Safety and Immunogenicity of Pneumococcal Conjugate Vaccines in a High-risk Population: A Randomized Controlled Trial of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine in Papua New Guinean Infants

William S Pomat,Anita H J van den Biggelaar,Sandra Wana,Jacinta P Francis,Vela Solomon,Andrew R Greenhill,Rebecca Ford,Tilda Orami,Megan Passey,Peter Jacoby,Lea-Ann Kirkham,Deborah Lehmann,Peter C Richmond,L Bele,M Dreyam,A Elizah,R Ford,J Francis,A Gihigupa,A Greenhill,S Javati,J Kave,W Kirarock,M Lai,B Martin,G Masiria,A Michael,L Moliki,B Nagepu,M Nenikuro,B Nivio,C Opa,T Orami,W S Pomat,G Saleu,P Siba,V Solomon,S Wana,L Wawae,M Yoannes,I Hwaihwanje,T Korowi,C Mond,P Wari,P Jacoby,D Lehmann,A van den Biggelaar,K Corscadden,C de Gier,L Kirkham,T Rahman,P Richmond,R Thornton,M Passey,

DOI: https://doi.org/10.1093/cid/ciy743

IF: 20.999

2018-09-03

Clinical Infectious Diseases

Abstract:BACKGROUND: There are little data on the immunogenicity of PCV10 and PCV13 in the same high-risk population.METHODS: PCV10 and PCV13 were studied head-to-head in a randomized controlled trial in Papua New Guinea in which 262 infants received 3 doses of PCV10 or PCV13 at 1, 2, and 3 months of age. Serotype-specific immunoglobulin G (IgG) concentrations, and pneumococcal and nontypeable Haemophilus influenzae (NTHi) carriage were assessed prevaccination and at 4 and 9 months of age. Infants were followed up for safety until 9 months of age.RESULTS: One month after the third dose of PCV10 or PCV13, ˃80% of infants had IgG concentrations ≥0.35µg/mL for vaccine serotypes, and 6 months postvaccination IgG concentrations ≥0.35 µg/mL were maintained for 8/10 shared PCV serotypes in > 75% of children vaccinated with either PCV10 or PCV13. Children carried a total of 65 different pneumococcal serotypes (plus nonserotypeable). At 4 months of age, 92% (95% confidence interval [CI] 85-96) of children vaccinated with PCV10 and 81% (95% CI 72-88) vaccinated with PCV13 were pneumococcal carriers (P = .023), whereas no differences were seen at 9 months of age, or for NTHi carriage. Both vaccines were well tolerated and not associated with serious adverse events.CONCLUSIONS: Infant vaccination with 3 doses of PCV10 or PCV13 is safe and immunogenic in a highly endemic setting; however, to significantly reduce pneumococcal disease in these settings, PCVs with broader serotype coverage and potency to reduce pneumococcal carriage are needed.CLINICAL TRIALS REGISTRATION: NCT01619462.

immunology,infectious diseases,microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the safety and immunogenicity of the 10 - valent pneumococcal conjugate vaccine (PCV10) and the 13 - valent pneumococcal conjugate vaccine (PCV13) in high - risk populations. Specifically, the study aims to evaluate the safety, immune response, and antibody persistence of these two vaccines in Papua New Guinean infants, and to explore the impact of the vaccines on bacterial carriage, thereby providing a scientific basis for the selection of appropriate pneumococcal vaccines in high - risk areas.

### Research Background
Pneumococcal diseases are one of the leading causes of death in children worldwide, especially in low - income countries. Although PCV10 and PCV13 have been widely used, there is relatively little comparative data on these two vaccines in high - risk populations. Papua New Guinea is a high - risk area, and infants have an extremely high risk of invasive pneumococcal disease (IPD) within the first year of life. Therefore, understanding the performance of these two vaccines in this specific population is crucial for formulating effective vaccination strategies.

### Research Objectives
1. **Safety**: Evaluate the safety of PCV10 and PCV13 in Papua New Guinean infants.
2. **Immunogenicity**: Evaluate the immune responses of the two vaccines in infants, including the levels of vaccine - serotype - specific IgG antibodies.
3. **Antibody Persistence**: Evaluate the persistence of the immune response, especially the antibody levels six months after vaccination.
4. **Bacterial Carriage**: Evaluate the impact of the vaccines on the carriage of pneumococci and non - typeable Haemophilus influenzae (NTHi).

### Research Methods
- **Design**: Randomized controlled trial.
- **Subjects**: 262 Papua New Guinean infants, randomly divided into two groups and vaccinated with PCV10 or PCV13 respectively.
- **Vaccination Time**: One dose was administered at 1, 2, and 3 months of age.
- **Detection Indicators**: Blood samples and nasopharyngeal swabs were collected before vaccination, at 4 months of age, and at 9 months of age to detect the levels of serotype - specific IgG antibodies and bacterial carriage.

### Main Findings
- **Safety**: Both vaccines were well - tolerated, and no serious adverse events were observed.
- **Immunogenicity**: One month after vaccination, more than 80% of infants had IgG antibody levels against vaccine serotypes that reached or exceeded 0.35 µg/mL. Six months later, most infants still maintained relatively high antibody levels.
- **Bacterial Carriage**: At 4 months of age, the pneumococcal carriage rate in the PCV10 group was significantly higher than that in the PCV13 group, but there was no significant difference at 9 months of age. There was no significant difference in the NTHi carriage rate between the two groups.

### Conclusions
- **Overall Conclusion**: PCV10 and PCV13 both have good safety and immunogenicity in Papua New Guinean infants in high - risk areas.
- **Limitations**: Although both vaccines are effective, in high - risk areas, due to the high density of bacterial carriage, the effect of the vaccines on reducing bacterial carriage is limited. Future research is needed to further optimize the application of vaccines in these areas, including considering booster doses and accelerated vaccination schedules.

Through this study, the authors hope to provide a scientific basis for the selection of appropriate pneumococcal vaccines in high - risk areas and promote the implementation of more effective vaccination strategies.